October 1, 2024
View Full PaperTable 3 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Key Points
Key points are not available for this paper at this time.
Abstract
Most common AEs (≥10% in either arm) in the overall population (16).